Home » Open Orphan (ORPH) » Open Orphan (ORPH) Upcoming Investor Events

Open Orphan (ORPH) Upcoming Investor Events

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at a series of investor events from the 4thSeptember to 10th October 2019.

Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance for all of the events and will be presenting to update existing and potential investors on the Company’s business plans for 2019-2020.

No new material information will be disclosed at any event.

A full schedule of the upcoming events is as follows:




Shares Magazine Investor Evening

September 4th 2019

18:00 – 21:30

London – Novotel Tower Bridge, EC3N 2NR

ShareSoc Growth Company Seminar

September 11th 2019


London – 65 Gresham Street, London, EC2V 7NQ

London South East Biotech Investor Evening

September 11th 2019


London – Brewers Hall, Aldermanbury Square, London EC2V 7HR

Shares Magazine Investor Evening

September 12th 2019

17:20 – 21:30

Edinburgh – Radisson Blu Hotel, EH1 1TH

Total Market Solutions

September 18th 2019 12:30-15:00

London, Moorgate

Proactive Investors One2One Forum

September 18th 2019

18:00 – 20:00

London – Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB in the Charles Suite (1st Floor)

Shares Magazine Investor Evening

October 10th 2019 18:00

Manchester – Macdonald Manchester Hotel, M1 2PG


Open Orphan Plc Tel: +353 1 5499 341
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.